Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis

Carcinogenesis

Volumn 37, Issue 5, 2016, Pages 461-470

  Madhavan, Dharanija ^a,b   Peng, Cike ^a,b   Wallwiener, Markus ^b   Zucknick, Manuela ^a,c   Nees, Juliane ^b   Schott, Sarah ^b   Rudolph, Anja ^a   Riethdorf, Sabine ^d   Trumpp, Andreas ^a,e   Pantel, Klaus ^d   Sohn, Christof ^b   Chang Claude, Jenny ^a   Schneeweiss, Andreas ^b   Burwinkel, Barbara ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Exp Hematology Group Heidelberg Institute for Stem Cell Technology and Experimental Medicine GGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 1260; MICRORNA 1274A; MICRORNA 141; MICRORNA 144; MICRORNA 183B; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 203; MICRORNA 210; MICRORNA 215; MICRORNA 365; MICRORNA 375; MICRORNA 429; MICRORNA 486 5P; MICRORNA 801; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MORBIDITY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR SUPPRESSOR GENE; BLOOD; BREAST TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84964882348     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw008     Document Type: Article

References (36)

1. Jemal, A., et al. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
2. Cardoso, F., et al. (2009) Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and followup. Ann. Oncol., 20, 15-18.
3. Lumachi, F., et al. (2000) Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res., 20, 4751-4755.
4. Harris, L., et al.; American Society of Clinical Oncology. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 25, 5287-5312.
5. Hanash, S.M., et al. (2011) Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol., 8, 142-150.
6. Alix-Panabières, C., et al. (2014) Technologies for detection of circulating tumor cells: facts and vision. Lab. Chip, 14, 57-62.
7. Largillier, R., et al. (2008) Prognostic factors in 1, 038 women with metastatic breast cancer. Ann. Oncol., 19, 2012-2019.
8. Taneja, P., et al. (2010) Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin. Med. Insights. Oncol., 4, 15-34.
9. Khanfir, A., et al. (2013) Prognostic factors and survival in metastatic breast cancer: A single institution experience. Rep. Pract. Oncol. Radiother., 18, 127-132.
10. De Cremoux, P., et al.; Breast Cancer Study Group of the Institut Curie. (2009) Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res., 29, 1475-1482.
11. Wang, Y., et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 365, 671-679.
12. Chim, S.S., et al. (2008) Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem., 54, 482-490.
13. Turchinovich, A., et al. (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res., 39, 7223-7233.
14. Zhao, H., et al. (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One, 5, e13735.
15. Cuk, K., et al. (2013) Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer, 132, 1602-1612.
16. Mar-Aguilar, F., et al. (2013) Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis. Markers, 34, 163-169.
17. Cuk, K., et al. (2013) Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS One, 8, e76729.
18. Madhavan, D., et al. (2013) Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front. Genet., 4, 116.
19. Madhavan, D., et al. (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res., 18, 5972-5982.
20. Roth, C., et al. (2010) Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res., 12, R90.
21. van Schooneveld, E., et al. (2012) Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res., 14, R34.
22. Eisenhauer, E.A., et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer, 45, 228-247.
23. R Core Team (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
24. Dvinge, H., et al. (2009) HTqPCR: High-throughput analysis and visualization of quantitative real-time PCR data in R. Bioinformatics, 25, 3325-3326.
25. Gentleman, R.C., et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol., 5, R80.
26. Andersen, C.L., et al. (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res., 64, 5245-5250.
27. Gregory, P.A., et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol., 10, 593-601.
28. Dykxhoorn, D.M., et al. (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One, 4, e7181.
29. Viticchiè, G., et al. (2011) MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle, 10, 1121-1131.
30. Ward, A., et al. (2013) Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene, 32, 1173-1182.
31. Tahiri, A., et al. (2014) Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis, 35, 76-85.
32. Yan, L.X., et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-2360.
33. Nie, J., et al. (2012) microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis, 33, 220-225.
34. Kang, S.M., et al. (2013) MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer. Cancer Lett., 335, 487-494.
35. Wang, K., et al. (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS One, 7, e41561.
36. Turchinovich, A., et al. (2012) Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol., 9, 1066-1075.